Book Value per Share: BrainStorm Cell Therapeutics (BCLI)
The absence of profitable assets and regulatory complexities are creating cash flow stagnation, as confirmed by the actual book value per share; the value of -0.94 reflects this status. Stability is ensured by distributing drug production across external US cGMP centers. Structural flexibility is maintained through the full outsourcing of research and production, which relieves Brainstorm Cell (BCLI) of excessive capital expenditures.
brainstorm-cell.com - analytical breakdowns and key metrics (BCLI)
Key analytical indicators for BrainStorm Cell Therapeutics (BCLI):
Price Chart Brainstorm Cell Therapeutics, Inc.|BCLI - Price Target Chart|Market Capitalization Brainstorm Cell Therapeutics Inc.|BCLI - Company Buyout Price|Net Assets per Single Share BrainStorm Cell Therapeutics|BCLI - Accounting Capitalization|Market Capitalization to Book Value Ratio brainstorm-cell.com|BCLI - Company Assets|Total Debt to Equity Ratio Brainstorm Cell|BCLI - Long-Term Debt to Capital|Short-Term Debt to Equity BrainStorm Cell Therapeutics|BCLI - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Brainstorm Cell Therapeutics Inc.
Fundamental company valuation:Brainstorm Cell Therapeutics, Inc., BCLI
For the biotech sector, where Brainstorm Cell (BCLI) focuses on the NurOwn platform and the approval of ALS therapy, this indicator reflects the actual net asset value available upon business liquidation. By analyzing the historical trend of the book value per share, an investor assesses the gap between the market price and equity minus liabilities, which is critical for risk assessment while awaiting Phase 3 clinical trial results.
Competitors of Brainstorm Cell (BCLI)
BIIB - Net Assets per Single Share|NBIX - Net Assets per Single Share|Regencell Bioscience - Book Value per Share|AXSM (axsome.com) - Net Assets per Share|Net Assets per Single Share ACADIA Pharmaceuticals Inc. (ACAD)|Equity per Share Xenon Pharmaceuticals Inc.|Viking Pharma - Book Value per Share|Net Asset Value per Share Supernus Corp SUPN|Accounting Value per Share CPRX (Catalyst Pharmaceuticals)|denalitherapeutics.com - Book Value per Share|Net Assets per Single Share Harmony Biosciences Holdings, Inc. (HRMY)|BHVN: Accounting Value of a Share|Net Assets per Single Share AMLX|Trevi Corp (TRVI) - Net Asset Value per Share|Book Value per Share Praxis Precision Medicines|Net Assets per Single Share AVXL|CeriBell (CBLL) - Net Assets per Single Share|Accounting Value of a Share Prothena Corporation (PRTA)|Book Value per Share ALEC (Alector)|Book Value per Share Annexon Biosciences Inc. ANNX|Book Value per Share OMER (Omeros Corp.)|NGNE: Net Assets per Share|Net Assets per Single Share AC Immune SA|VYGR (Voyager Therapeutics Inc) - Equity per Share|NMRA: Net Assets per Single Share|Net Assets per Share Scilex Holding Company, Inc. (SCLX)|Accounting Value per Share Tevogen Bio Holdings|Book Price of a Share ACOG (alphacognition.com)|CGTX: Net Assets per Single Share|Inhibikase Therapeutics Inc - Net Asset Value per Share|Net Assets per Single Share Cassava (SAVA)|ASRT: Accounting Value of a Share|COYA (coyatherapeutics.com) - Net Assets per Single Share|Accounting Value per Share Vistagen|OVID - Accounting Value per Share|Accounting Value of a Share Acumen Pharmaceuticals Inc.|Book Value per Share CRVO (CervoMed Inc)|Accounting Value per Share alteritytherapeutics.com (ATHE)|CLNN: Book Value per Share|PepGen Inc - Net Asset Value per Share|JUNS - Net Assets per Single Share|RLMD: Net Assets per Single Share|Annovis Bio Corp (ANVS) - Net Assets per Single Share|Grace Therapeutics (GRCE) - Net Assets per Single Share|Book Value per Share Firefly Neuroscience, Inc|Net Assets per Single Share ANEW Medical, Inc.|Book Value per Share NRSN (NeuroSense Therapeutics)|Accounting Value per Share RVPH (Reviva Pharmaceuticals Holdings Inc.)|Net Assets per Single Share MetaVia MTVA|Net Assets per Single Share NeurAxis Inc NRXS|Book Value per Share HSDT (Helius Medical Technologies Inc.)|PASG: Net Assets per Share|Net Assets per Single Share bionomics.com.au|Minerva Neurosciences Inc (NERV) - Equity per Share|Book Value per Share ATHA (Athira)|Net Asset Value per Share Addex (ADXN)|Accounting Value per Share ALZN|Book Value per Share CYCN (cyclerion.com)|Net Assets per Single Share Protagenic Therapeutics, Inc.|Pasithea Therapeutics Corp - Accounting Value of a Share|CRGT (Cortigent Medical) - Net Assets per Single Share|ATXI - Net Asset Value per Share|Cara Therapeutics, Inc. (CARA) - Book Value per Share|CHRO (chromocell.com) - Net Assets per Single Share|ELYM - Net Assets per Single Share|Accounting Value of a Share Intra-Cellular|Book Value per Share LBPH|Book Value per Share Marinus Pharma (MRNS)|Book Value per Share NKGN|neurobopharma.com - Net Assets per Share|Sage Therapeutics (SAGE) - Net Assets per Single Share|SNPX: Equity per Share|Trevena, Inc - Net Assets per Single Share|Net Assets per Share Vigil Neuroscience, Inc.|Anew Medical (WENA) - Accounting Value per Share|Book Price of a Share CERE